Skip to main content
. 2023 Oct 28;13(11):1587. doi: 10.3390/biom13111587

Figure 1.

Figure 1

KRAS codon 12 mutational signature in lung and pancreatic cancer landscape. (A) KRAS G12C mutation is more prevalent in non-small cell lung cancer (~40%) compared to the KRAS G12D mutation. (B) Conversely, in pancreatic cancer, KRASG12D mutation is the most frequently observed mutation. Cancer cells with the respective mutations are favored for their fitness in the fitness landscapes prevailing in the lung and pancreas, respectively. Figure 1 was made using BioRender.com (1 September 2023).